上海交大赵大海接受央视专访：中国大规模新冠疫苗接种已准备
上海交通大学国际与公共事务学院博士生导师、上海交通大学-耶鲁大学卫生政策联合研究中心执行主任赵大海，自新冠肺炎疫情暴发以来，对于新冠疫情暴发、防控以及卫生政策第44次接受中央电视台专访，也是第69次接受央视、上视专访。2020年12月19日，赵大海在中央电视台英语频道的《今日世界》节目，就当日正在举行的国务院联防联控的新冠疫苗接种新闻发布会进行了直播评论。现将评论内容翻译并摘录如下。
主持人：您对本次国务院联防联控关于新冠疫苗专场的新闻发布会，有何看法？
赵大海：当我听新闻发布会时，所有的信息都是令人兴奋的。首先，中国卫生部门对新冠疫苗接种的所有细节都进行了翔实的规划。中国已经为大规模接种新冠疫苗做好了充分准备。譬如，公众到哪里去接种疫苗，以及中国已建立了完善的疫苗不良反应监测机制和负责机构。根据本次新闻发布会，所有的关于疫苗接种的细节都已准备好了。第二，新冠疫苗接种的公平、科学分配方案已确定。对于包括医务人员、交通运输行业从业者等疫苗接种的重点人群已确定好了。重点人群的设定标准是根据这一行业的人群具有更大的可能感染新冠肺炎病毒，而与人群的贫富、性别等均无关联。我相信新冠疫苗的这种分配方案是科学、公平的，也是合乎伦理道德的。
主持人：让我们聊一下新冠疫苗临床三期的话题。中国疫苗的所有临床三期试验都在海外。考虑到中国新冠疫情在很早期就已控制住了，最新数据显示，中国新冠疫苗在海外做了7万5千个志愿者的测试。中国的新冠疫苗试验是不是坚持了安全性第一的原则？
赵大海：是的，我坚信中国新冠疫苗的临床三期绝对是将安全性作为了首要原则。对于这一点，毋庸置疑。
主持人：让我们聊一下新冠疫苗的大规模生产的话题。一旦新冠疫苗被批准生产，实现大规模生产应该是不会太容易的。您觉得新冠疫苗大规模生产的挑战有哪些？
赵大海：关于新冠疫苗的大规模生产，我认为一定会存在一系列的挑战和障碍。最重要的挑战就是大规模生产新冠疫苗所需的原料储备。众所周知，新冠疫苗的生产原料并不是在所有可以生产新冠疫苗的国家都是完全充沛的。对于中国而言，虽然我们已做到了新冠疫苗生产的大量原料储备，但我们也不敢说，我们的新冠疫苗生产的原料已完全充足。因此，我认为生产新冠疫苗的原料储备是最重要的一项挑战。
供稿者：国务学院
日期：2020年12月19日
Dahai ZHAO’s Exclusive Interview with CGTN: China prepares large-scale rollout of COVID-19 vaccines
Dahai Zhao, a doctoral supervisor at the School of International and Public Affairs of Shanghai Jiao Tong University and Executive Director of Shanghai Jiao Tong University-Yale University Joint Research Center for Health Policy, has been interviewed by CGTN for the 44nd time (the 69nd time by CGTN / ShanghaiTV) since the COVID-19 pandemic. On December 19, 2020, Zhao commented on the state council's interagency task force holding a press conference on China's COVID-19 vaccination on “The World Today” of CGTN.
Anchor: What are the highlights of the press conference?
ZHAO: When I listen to the press conference, all news is exciting. First, China health authorities have carefully regulated all details of vaccine inoculation. In a word, China has fully prepared for the mass COVID-19 vaccine inoculation. For example, where and how to get the vaccine inoculation; China has built a complete monitoring mechanism and organization to deal with the adverse reactions of the vaccines. According to the press conference, all these issues have been fully considered and prepared. Second, fair and scientific distribution of COVID-19 vaccine inoculations has been designed. The key population has been defined such as medical workers, transportation workers. The standard of the key population is whether this group of people have more probability to be infected by the COVID-19 virus. The distribution is not related to whether this person is rich or poor, male or female. I believe this distribution is scientific, fair, and ethical.
Anchor: Let's talk about phase III of the COVID-19 vaccine. All phase III clinical trials of Chinese vaccines are overseas. Given that the COVID-19 outbreak in China has been contained at an early stage, the latest figures show that the Chinese vaccine has been tested in 75,000 volunteers overseas. Does China's COVID-19 trial adhere to the principle of safety first?
ZHAO: Yes, I firmly believe that safety is a top priority in phase III clinical trials of COVID-19 vaccines in China. There is no doubt about it.
Anchor: Let's talk about the mass production of COVID-19 vaccines. Once the COVID-19 vaccine is approved for production, mass production should not be easy. What do you think are the challenges of mass production of the COVID-19 vaccine?
ZHAO: As for the large-scale production of the COVID-19 vaccine, I think there will be a series of challenges and obstacles. The most important challenge is the stock of raw materials needed for the mass production of COVID-19 vaccines. It is well known that the raw materials for COVID-19 production are not fully available in all countries where COVID-19 production is possible. For China, although we have achieved a large stock of raw materials for the production of the COVID-19 vaccine, we dare not say that we have fully sufficient raw materials for the production of the COVID-19 vaccine. Therefore, I believe that the raw material reserve for the production of the COVID-19 vaccine is the most important challenge.
Contributor: SIPA, SJTU
Data: December 19, 2020